MedWatch

New Lundbeck study of depression drug meets endpoint

Major depressive disorder and dementia often go hand-in-hand, and patients with both who were treated with Trintellix/Brintellix saw improvements in depression symptoms and cognitive performance.

Photo: Jens Dresling

Lundbeck’s depression drug Trintellix/Brintellix (vortioxetine) has met its endpoint in a study involving people with major depressive disorder (MDD) and co-morbid early dementia, the company announces in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs